BioWorld

Jan. 13, 2014

Money Raised By Biotech In 2014 vs. 2013

Venture capital holds steady but additional sources needed

It is that time of year again when the biotech lens sets its focus squarely on San Francisco with more than 12,000 business executives, investors and analysts heading to town for the J.P. Morgan Healthcare, Biotech Showcase and OneMedForum events. The common denominator for all these meetings is money. Read More

Reverse splits couldn’t hold these companies down

Reverse splits have a bad reputation amongst investors, causing biotechs, for the most part, to avoid them at all cost. Read More

Week in Review

Money Raised By Biotech Jan. 1 - 9, 2014

Word on the Street

Week in Washington

Phase I clinical trials update: December 2013

Phase II clinical trials update: December 2013

Phase III clinical trials update: December 2013

American Society of Hematology: December 2013

Pharma clinical and FDA action update: December 2013

Non-U.S. clinical trials and regulatory actions: December 2013

FDA submissions, approvals & other actions: December 2013

The Week's Biggest Gainers And Losers

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...